



Welcome to the Launch of Biocon's Breakthrough Innovation

ALWAYS
ALZUMabTM
A novel biologic

PARADIGM CHANGED

For **Psoriasis**
Treatment

PRESS MEET
Bangalore, August 10, 2013



Autoimmune Diseases are on the Rise Globally



Autoimmune Disease Segment includes over 100 Diseases



**Currently Available Therapies
Target only 10 of the
Over 100
Unique Autoimmune
Diseases**




**ALZUMAb™ Novel Biologic
Developed by Biocon
will Address Unmet Needs
of several Challenging
Autoimmune Diseases**



ALWAYS
ALZUMAb[™]
A novel biologic

'FIRST-IN-CLASS' NOVEL BIOLOGIC FOR PSORIASIS




- Itolizumab (ALZUMAb[™]): An **anti-CD6 novel antibody** developed in India by Biocon
- Will **Change the treatment paradigm** for Psoriasis in India
- Will **address unmet need** of 1-2% **Indian population** suffering from Psoriasis
- Recognition of **Quality of Research** at Biocon

- World's **first anti-CD6 monoclonal antibody** to complete its 'Lab to Market' journey
- **Unique MOA: Front runner** in the **Th 17 pathway- an evolving Science**
- An **Immunomodulator** against available immuno-suppressants
- **Excellent safety and efficacy profile** with **longer remission periods** and **low infection rates** vis-à-vis other approved therapies
- **Promising** preclinical and clinical **efficacy data** in **other autoimmune diseases**



- **New data** demonstrates **Th17 cells** play **critical** role in **autoimmunity**
- Biocon is a **recognized front-runner**; has a **novel MAb** with MOA and clinical data involving **Th17 pathway**
- **ALZUMAb™** works **upstream** modulating CD6 mediated co-stimulation, inhibiting Lymphocyte proliferation and pro-inflammatory cytokine production
- **Available biologics** act **downstream** and have **high infection** and shorter **remission periods**

Itolizumab: Novel Mechanism of Action
Validated by New Evolving Science



Patient 1: Returns to Normal Life Post Treatment

Before



After



Regained her
Normal
Life.....post
her treatment
with
ALZUMAb™

- A young woman suffering from Psoriasis for eleven years, treated with ALZUMAb™ for eight weeks had 97% improvement
- Uptil six month observation period no reoccurrence reported

**Latest picture after
4.5 years of Last dose**



Patient 2: Completely Cured of Disease Post Treatment



Before

After



- A young man suffering from Psoriasis for six years, failed to respond to various treatments
- Post an eight weeks treatment with ALZUMAb™ he was free from Psoriasis
- Uptil six month observation period no reoccurrence reported

**Achieved
complete
Remission...
.....post eight
weeks
treatment
with
ALZUMAb™**



Strategic Focus on Biologics

- **Monoclonal antibodies and recombinant proteins**
- Research around **novel programs** focused on **Oncology** and **Immunology**
- Has provided **leading-edge clinical therapies** in the marketplace at an **affordable cost**

Novel Biologics Introduced in India

- **Biomab EGFR**, for metastatic Head & Neck cancer introduced in 2006 in India
- Over **5500 patients** effectively treated with **BIOMAb EGFR** in India –
- **2nd Novel Biologic, ALZUMAb™** the **world's first anti-CD6 antibody** for chronic plaque **psoriasis** launched in India in **2013**



- **Itolizumab is 2nd novel biologic from Biocon's labs**
- **Has the potential to make global impact**
- **Partnership discussions initiated for global development of this late stage opportunity**
- **Committed to ensure our innovative assets reach patients with autoimmune diseases the world over**
- **First instance of a breakthrough innovation that will be taken from India to the developed world**



- Our **commitment to research and innovation** has enabled us to bring transformative innovation to Indian patients
- Lends **credibility to our innovation model**
- **Biocon** one of the **highest R&D spenders**
- Our **innovation and IP** focused on **creating enduring value** for our **stakeholders**



Thank You

